IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$7.65 USD
-0.31 (-3.89%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $7.63 -0.02 (-0.26%) 6:28 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
IGM Biosciences, Inc. [IGMS]
Reports for Purchase
Showing records 1 - 20 ( 83 total )
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2023 Financials Reported; Reiterate Neutral; Adjusting PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; Possible Aplitabart Update by YE:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Day 3 Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Re-Prioritized; Downgrading to Neutral With $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for IGMS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Datasets Expected; 3Q23 Financials; Lowering PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Checking in on Aplitabart, Imvotamab
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Aplitabart (IGM-8444) Cohorts Ongoing
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
EHA 2023 Roundup for Covered Companies (Part 1)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-8444 Shows Encouraging Activity; 1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Quarter of Execution in the Books
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D